XML 65 R38.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Segment and Related Information - Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense (Detail) (USD $) In Thousands, unless otherwise specified | 3 Months Ended | 6 Months Ended
--- | --- | ---
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2013
Segment Reporting Information [Line Items] |  |  |  |
Revenue | $ 184,393 us-gaap_Revenues | $ 204,060 us-gaap_Revenues | $ 353,230 us-gaap_Revenues | $ 406,527 us-gaap_Revenues
Depreciation and amortization | 6,036 us-gaap_DepreciationAndAmortization | 2,438 us-gaap_DepreciationAndAmortization | 11,990 us-gaap_DepreciationAndAmortization | 4,811 us-gaap_DepreciationAndAmortization
Segment operating income (loss) | 36,342 us-gaap_OperatingIncomeLoss | 82,999 us-gaap_OperatingIncomeLoss | 62,262 us-gaap_OperatingIncomeLoss | 165,903 us-gaap_OperatingIncomeLoss
Molecular Diagnostics |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenue | 179,149 us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = mygn_MolecularDiagnosticsMember | 196,158 us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = mygn_MolecularDiagnosticsMember | 343,656 us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = mygn_MolecularDiagnosticsMember | 389,144 us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = mygn_MolecularDiagnosticsMember
Depreciation and amortization | 4,991 us-gaap_DepreciationAndAmortization / us-gaap_StatementBusinessSegmentsAxis = mygn_MolecularDiagnosticsMember | 1,467 us-gaap_DepreciationAndAmortization / us-gaap_StatementBusinessSegmentsAxis = mygn_MolecularDiagnosticsMember | 9,969 us-gaap_DepreciationAndAmortization / us-gaap_StatementBusinessSegmentsAxis = mygn_MolecularDiagnosticsMember | 2,830 us-gaap_DepreciationAndAmortization / us-gaap_StatementBusinessSegmentsAxis = mygn_MolecularDiagnosticsMember
Segment operating income (loss) | 59,017 us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = mygn_MolecularDiagnosticsMember | 98,233 us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = mygn_MolecularDiagnosticsMember | 104,101 us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = mygn_MolecularDiagnosticsMember | 195,981 us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = mygn_MolecularDiagnosticsMember
Pharmaceutical and Clinical Services |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenue | 5,244 us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = mygn_PharmaceuticalAndClinicalServicesMember | 7,902 us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = mygn_PharmaceuticalAndClinicalServicesMember | 9,574 us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = mygn_PharmaceuticalAndClinicalServicesMember | 17,383 us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = mygn_PharmaceuticalAndClinicalServicesMember
Depreciation and amortization | 450 us-gaap_DepreciationAndAmortization / us-gaap_StatementBusinessSegmentsAxis = mygn_PharmaceuticalAndClinicalServicesMember | 489 us-gaap_DepreciationAndAmortization / us-gaap_StatementBusinessSegmentsAxis = mygn_PharmaceuticalAndClinicalServicesMember | 899 us-gaap_DepreciationAndAmortization / us-gaap_StatementBusinessSegmentsAxis = mygn_PharmaceuticalAndClinicalServicesMember | 989 us-gaap_DepreciationAndAmortization / us-gaap_StatementBusinessSegmentsAxis = mygn_PharmaceuticalAndClinicalServicesMember
Segment operating income (loss) | (1,011)us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = mygn_PharmaceuticalAndClinicalServicesMember | 1,052 us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = mygn_PharmaceuticalAndClinicalServicesMember | (2,794)us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = mygn_PharmaceuticalAndClinicalServicesMember | 2,889 us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = mygn_PharmaceuticalAndClinicalServicesMember
Research |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Depreciation and amortization | 595 us-gaap_DepreciationAndAmortization / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchMember | 482 us-gaap_DepreciationAndAmortization / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchMember | 1,122 us-gaap_DepreciationAndAmortization / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchMember | 992 us-gaap_DepreciationAndAmortization / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchMember
Segment operating income (loss) | $ (21,664)us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchMember | $ (16,286)us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchMember | $ (39,045)us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchMember | $ (32,967)us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchMember

X
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details
Name: | us-gaap_DepreciationAndAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mygn_MolecularDiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mygn_PharmaceuticalAndClinicalServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_ResearchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |